No, no a thousand times no. You can't make me. I only asked a question about which stock.
I did not write this but agree with it.
Some interesting numbers from the Wall Street Journal (Dec. 2013):
“...the number of diabetic patients has continued growing from 246 million in 2007 to 382 million in 2013 at a compound annual growth rate of 7.6%. And insulin as the important diabetes medication has also seen increasing market size.
In 2012 the global insulin market size reached US $20.8 billion, a year-on-year rise of 12.9%, basically monopolized by Novo Nordisk, Sanofi and Eli Lilly, which altogether accounted for 88.7% of market share.
Being the biggest diabetes power in the world, China currently has 98.4 million patients, accounting for about 25.8% of the world’s total. With the maturing of national health insurance system and improvement of economic level, the Chinese insulin drug market size has been on the rise, with the CAGR in 2007-2012 up to 25.4%, well above that of the global insulin market size, and it is expected to maintain a CAGR of at least 15% in the next few years.”
The size of this market is staggering, almost too large to fathom and if inhaled Afreza is approved why would any diabetic want to use the old needle based insulin?
Mannkind is really onto something here, a 25 billion dollar market growing in double digits every year. This will be a game changer, a new paradigm in diabetic control.
Right now, without approval and obviously nothing in sales, investors have made Mannkind almost a 4 billion dollar company with a price per share around $9, that’s bigger than U.S Steel!
A year from now, Mannkind can easily be the next Tesla type breakout stock of the year. It could be trading at $65 per share. And by the end of 2016, we can be looking at $250 per share.
Milestone events:
1. FDA decision comes by July 15th or sooner.
2. Partnership announcement with a major pharmaceutical company shortly thereafter (by August 15th).
3. First sales reports in Q2 or Q3 in 2015.
4. First year of sales reports by Q2 or Q3 in 2016.
Another writer thinks the following:
MNKD is a short killer. There are much better stocks out there to short. This one is just too dangerous. There are numerous catalysts:
1. FDA approval
2. Partnership announcement
3. Overseas approval (huge!)
4. Massive revenue growth due the size of the diabetes market.
The other stocks you compare MNKD to don’t operate in the diabetes space and aren’t fundamental game changers like going from a needle to a inhalable device which is the only inhalable insulin on this planet. MNKD has the market for inhalable insulin all to itself. The revenue growth that could come, and quickly, is staggering.
So do your due diligence but MNKD might be a winner.
http://www.mannkindcorp.com/mobile_site/index.html?pagekey=index/index.html
Alfred Mann foundation
http://aemf.org